When to Use OncoK9 

OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using NGS technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. It is recommended as an aid in diagnosis for dogs in which cancer is suspected based on clinical findings. The test can also be considered by clinicians for early cancer detection, with serial annual testing, in dogs without clinical signs, beginning at seven years of age or potentially younger for breeds that are predisposed to cancer. Report includes detection/not detection of a cancer signal and does not provide the origin (except for hematological malignancies, such as lymphoma, where a Cancer Signal Origin Prediction will be provided.) As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient’s medical history and clinical presentation.

OncoK9 Workflow 

1. Blood collection at the clinic — OncoK9 liquid biopsy uses only one tablespoon of blood and requires no special handling or storage. 
2. Sample arrives at PetDx lab — Shipped from Antech to PetDx overnight at ambient temperature.  
3. Sample processing — Accessioning and centrifugation to separate plasma and WBCs. 
4. DNA extraction — Isolate cell-free DNA (cfDNA) and genomic DNA (gDNA) for analysis.* 
5. DNA library preparation — Attach-specific adapters to cfDNA and gDNA fragments in preparation for sequencing.* 
6. DNA sequencing — Next-generation sequencing (NGS) at PetDx to detect cancer-associated genomic alterations.  
7. Bioinformatics — NGS data analysis with algorithms optimized for the canine genome.* 
8. Lab director review — Consolidation and interpretation of findings and clinical report generation.* 
9. Clinical report delivery — Access through Antech Online. 

*Denotes workflow steps that include proprietary PetDx methods, techniques and/or algorithms.